Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Crinetics Pharmaceuticals (CRNX) Receivables - Other (2017 - 2025)

Crinetics Pharmaceuticals has reported Receivables - Other over the past 9 years, most recently at $7.8 million for Q4 2025.

  • For Q4 2025, Receivables - Other fell 6.64% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $7.8 million, down 6.64%, while the annual FY2025 figure was $7.8 million, 6.64% down from the prior year.
  • Receivables - Other for Q4 2025 was $7.8 million at Crinetics Pharmaceuticals, up from $6.3 million in the prior quarter.
  • Over five years, Receivables - Other peaked at $8.4 million in Q2 2025 and troughed at $85000.0 in Q1 2021.
  • A 5-year average of $2.8 million and a median of $1.3 million in 2022 define the central range for Receivables - Other.
  • Biggest five-year swings in Receivables - Other: plummeted 93.35% in 2023 and later soared 9133.33% in 2024.
  • Year by year, Receivables - Other stood at $553000.0 in 2021, then soared by 144.67% to $1.4 million in 2022, then plummeted by 93.35% to $90000.0 in 2023, then soared by 9133.33% to $8.3 million in 2024, then fell by 6.64% to $7.8 million in 2025.
  • Business Quant data shows Receivables - Other for CRNX at $7.8 million in Q4 2025, $6.3 million in Q3 2025, and $8.4 million in Q2 2025.